[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1074268T3 - IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme - Google Patents

IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme

Info

Publication number
DK1074268T3
DK1074268T3 DK99907951T DK99907951T DK1074268T3 DK 1074268 T3 DK1074268 T3 DK 1074268T3 DK 99907951 T DK99907951 T DK 99907951T DK 99907951 T DK99907951 T DK 99907951T DK 1074268 T3 DK1074268 T3 DK 1074268T3
Authority
DK
Denmark
Prior art keywords
inflammatory bowel
preventative
therapeutic agents
receptor antagonist
antagonist antibody
Prior art date
Application number
DK99907951T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Mitsunari Yamamoto
Hiroaki Ito
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13339502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1074268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1074268T3 publication Critical patent/DK1074268T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK99907951T 1998-03-17 1999-03-16 IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme DK1074268T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6725098 1998-03-17
PCT/JP1999/001298 WO1999047170A1 (fr) 1998-03-17 1999-03-16 Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6

Publications (1)

Publication Number Publication Date
DK1074268T3 true DK1074268T3 (da) 2008-04-28

Family

ID=13339502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99907951T DK1074268T3 (da) 1998-03-17 1999-03-16 IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme

Country Status (19)

Country Link
US (2) US6723319B1 (da)
EP (1) EP1074268B1 (da)
JP (1) JP4124573B2 (da)
KR (1) KR100407811B1 (da)
CN (2) CN100374159C (da)
AT (1) ATE383875T1 (da)
AU (1) AU754006B2 (da)
CA (1) CA2324115C (da)
CZ (1) CZ297083B6 (da)
DE (1) DE69937994T2 (da)
DK (1) DK1074268T3 (da)
ES (1) ES2299241T3 (da)
HK (2) HK1033911A1 (da)
HU (1) HU225539B1 (da)
NO (1) NO327718B1 (da)
PL (1) PL201461B1 (da)
PT (1) PT1074268E (da)
RU (1) RU2195960C2 (da)
WO (1) WO1999047170A1 (da)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CZ296979B6 (cs) * 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
ATE407696T1 (de) 1997-03-21 2008-09-15 Chugai Pharmaceutical Co Ltd Vorbeugende- oder heilmittel zur behandlung von multipler sklerose, mit antagonistischen anti-il6-rezeptor antikörpern als wirkstoff
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20050118163A1 (en) * 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
CN1678744B (zh) * 2002-08-30 2010-05-26 财团法人化学及血清疗法研究所 人的抗人白细胞介素-6抗体以及所述抗体的片段
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2539061A1 (en) * 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg Use of an antagonist of il-6 for treating il-6-mediated diseases
WO2005037315A1 (ja) * 2003-10-17 2005-04-28 Chugai Seiyaku Kabushiki Kaisha 中皮腫治療剤
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
US8398980B2 (en) * 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JPWO2007061029A1 (ja) * 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
ES2685915T3 (es) 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
DK2009101T3 (da) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antistofmodifikationsfremgangsmåde til oprensning af et bispecifikt antistof
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
MX2009001110A (es) 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
CA2670583A1 (en) * 2006-11-30 2008-06-05 Medimmune, Llc Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤
BRPI0806812B8 (pt) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
MX349322B (es) 2007-05-21 2017-07-21 Alderbio Holdings Llc Anticuerpos para il-6 y sus usos.
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CN101939425B (zh) * 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
BRPI0821110B8 (pt) * 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TR201808535T4 (tr) * 2008-04-11 2018-07-23 Chugai Pharmaceutical Co Ltd İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
CN102256623A (zh) * 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US20120034212A1 (en) * 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
NZ708314A (en) 2009-03-18 2017-08-25 Resverlogix Corp Quinazolinones for use as anticancer agents
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PL2421533T3 (pl) 2009-04-22 2019-05-31 Resverlogix Corp Nowe środki przeciwzapalne
SG176074A1 (en) 2009-05-15 2011-12-29 Chugai Pharmaceutical Co Ltd Anti-axl antibody
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
KR101985153B1 (ko) 2009-10-26 2019-05-31 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US9724410B2 (en) 2009-11-24 2017-08-08 Alderbio Holdings Llc Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍t細胞応答増強剤
KR20130086628A (ko) 2010-11-08 2013-08-02 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3395836B1 (en) 2011-01-28 2021-04-28 Sanofi Biotechnology Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9402898B2 (en) 2012-01-23 2016-08-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
JP6117915B2 (ja) 2012-05-21 2017-04-19 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーKorea Research Institute Of Bioscience And Biotechnology ミゾコウジュの抽出物またはその分画物を有効成分として含む、stat3媒介性疾患の予防または治療用医薬組成物
US10822420B2 (en) * 2012-09-13 2020-11-03 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
JP6563910B2 (ja) 2013-07-04 2019-08-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI805565B (zh) 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University TREATMENT OF DIURETIC RESISTANCE
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
PE20211196A1 (es) 2018-01-05 2021-07-01 Novo Nordisk As Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
TW202413402A (zh) 2018-03-15 2024-04-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
MX2021009242A (es) 2019-01-31 2021-10-26 Sanofi Biotechnology Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica.
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2023508592A (ja) * 2019-12-31 2023-03-02 ペプチノフ 術後痛を予防又は治療するための医薬組成物
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Bsf▲下2▼アンタゴニスト
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
PT97124A (pt) 1990-03-23 1991-12-31 Gist Brocades Nv Processo para a prparacao de composicoes inibidoras de interleucina - 6 (il-6)
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン6拮抗剤、及びペプチド類または医薬として許容されるその塩類
EP0784482A2 (en) 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
EP0766564A4 (en) 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
JPH0850829A (ja) 1994-08-05 1996-02-20 Tokai Rika Co Ltd レバースイッチ
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
EP2077120A3 (en) 1994-10-07 2009-07-15 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
CZ296979B6 (cs) 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
JPH08245414A (ja) * 1995-01-27 1996-09-24 Private Biolog Corp Il−6関連疾患の治療用組成物および方法
JP4540132B2 (ja) 1995-02-13 2010-09-08 中外製薬株式会社 Il−6レセプター抗体を含んでなる筋蛋白分解抑制剤
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤
US5571513A (en) * 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
WO1996040966A1 (en) 1995-06-07 1996-12-19 Private Biologicals Corporation Compositions and methods of treating il-6 associated diseases
WO1997024340A1 (en) 1995-12-27 1997-07-10 Takeda Chemical Industries, Ltd. Oxazole derivatives, their production and use
JPH09235276A (ja) 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
DK0907737T3 (da) * 1996-04-09 2005-06-27 Applied Research Systems IL-6-mutein
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2481535C (en) 2002-04-12 2010-08-17 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
PL201461B1 (pl) 2009-04-30
ES2299241T3 (es) 2008-05-16
HUP0101694A3 (en) 2003-08-28
EP1074268A4 (en) 2002-11-20
CN1297357A (zh) 2001-05-30
AU754006B2 (en) 2002-10-31
US7824674B2 (en) 2010-11-02
DE69937994T2 (de) 2008-12-24
CA2324115A1 (en) 1999-09-23
HU225539B1 (en) 2007-02-28
JP4124573B2 (ja) 2008-07-23
KR20010041933A (ko) 2001-05-25
DE69937994D1 (de) 2008-03-06
KR100407811B1 (ko) 2003-12-01
RU2195960C2 (ru) 2003-01-10
NO327718B1 (no) 2009-09-14
HK1033911A1 (en) 2001-10-05
NO20004581D0 (no) 2000-09-14
NO20004581L (no) 2000-11-10
PL342938A1 (en) 2001-07-16
WO1999047170A1 (fr) 1999-09-23
ATE383875T1 (de) 2008-02-15
US20040071706A1 (en) 2004-04-15
HK1036018A1 (en) 2001-12-21
CZ297083B6 (cs) 2006-09-13
CN100374159C (zh) 2008-03-12
US6723319B1 (en) 2004-04-20
AU2748199A (en) 1999-10-11
HUP0101694A1 (hu) 2002-12-28
CN101239185A (zh) 2008-08-13
EP1074268A1 (en) 2001-02-07
CZ20003297A3 (cs) 2001-02-14
PT1074268E (pt) 2008-02-28
CA2324115C (en) 2008-12-23
EP1074268B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
DK1074268T3 (da) IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
HK1059040A1 (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
NO933239D0 (no) Bioeroderbar innretning for administering av aktive ingredienser
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
FI941396A0 (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
DK0733628T3 (da) 5-substituerede 3-(1,2,3,6-tetrahydropyridin-4-yl)- og 3-(piperidin-4-yl)-1H-indoler: 5HT1F-agonister
NO975713D0 (no) Chelaterende polymere som kontrastmidler for medisinsk billeddannelse
DK1024854T3 (da) Forbindelsesindretning til medicinsk brug
FI970530A0 (fi) Koostumus aktiivisen aineen selektiiviseksi vapauttamiseksi
IT1295645B1 (it) Apparecchio per l'elettroemanazione di principi attivi.
DE69330631D1 (de) Trennmittel
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
TR28732A (tr) Hijyenik temizlik bilesimi ve bu bilesimi püskürtmeye mahsus cihaz.
NO954183L (no) Diagnostisk avbildningsmiddel
FR2747230B1 (fr) Bouton d'arret d'urgence cadenassable
FR2695297B1 (fr) Composition d'agent désinfectant.
KR970000260U (ko) 의자용 다리부의 결합장치
FR2696773B1 (fr) Arrangement de bâtiments destinés à l'élevage d'animaux.
KR950022816U (ko) 발포제볼(Ball) 성형용 발포제 주입장치
KR940000465U (ko) 캣취볼 놀이용 캣취글러브
ITRM940114A0 (it) Dispositivo per gioco di abilita' con bilie a doppio percorso.
KR970020844U (ko) 숫 송아지 거세 장치
IT221262Z2 (it) Nodo sferico per strutture metalliche reticolari spaziali.